Sandoz Recalls Cefazolin Due to Mispackaging, Opens Biosimilar Facility in Slovenia

Sandoz Recalls Cefazolin Due to Mispackaging, Opens Biosimilar Facility in Slovenia

The company is voluntarily recalling one lot of cefazolin for injection, USP, 1 gram per vial due to customer complaints of the wrong product being included in a carton.

Antibiotic Recalled: Sandoz’s Cefazolin Recall Highlights Growing Risks in Pharmaceutical Packaging Flaws

This article was originally published by Willow Tohi at Natural News.  Sandoz’s Cefazolin shipment included the wrong antibiotic (Penicillin G), risking severe allergic reactions and antibiotic resistance. FDA warns misadministered doses could cause anaphylaxis, renal failure, and treatment failures in severe infections. Recent Amneal recalls and Johnson & Johnson scandals underscore systemic lax industry oversight. Recipients urged to retur…

Sandoz breaks ground on US$440m biosimilar facility in Slovenia - European Biotechnology Magazine

Biosimilar major Sandoz has started construction of an additional US$440m biosimilar facility near Ljubljana and it set to expand its investment footprint in Slovenia by US$1.1bn. The post Sandoz breaks ground on US$440m biosimilar facility in Slovenia appeared first on European Biotechnology Magazine.